Resources

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease

Product: — Cochrane Library

Drug Interventions Treatments

www.cochranelibrary.com Last Updated: March 16, 2021

Also available in Français

Tocilizumab for Hospitalized Patients with COVID-19

Product: — Science Table

Drug Interventions Hospital Care Treatments

covid19-sciencetable.ca Last Updated: March 1, 2021

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19

Product: — Science Table

Drug Interventions Infectious Diseases & Clinical Care Treatments

covid19-sciencetable.ca Last Updated: February 25, 2021

Best Practices for Limiting the Transmission of COVID‑19 Variants of Concern

Product: — Evidence Synthesis Network

Community Prevention & Transmission Public Prevention Transmission

esnetwork.ca Last Updated: February 24, 2021

Remdesivir: Evidence Review and Appraisal

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: February 19, 2021

Also available in Français

Ivermectin for the Treatment and Prevention of COVID-19

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: February 17, 2021

Also available in Français

Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19

Product: — Cochrane Library

Drug Interventions Treatments

www.cochranelibrary.com Last Updated: February 12, 2021

Also available in Français

Low Molecular Weight Heparin for Thromboprophylaxis of COVID‑19 Positive Long-Term Care Home Residents

Product: — Evidence Synthesis Network

Drug Interventions Long-term & Community Care Long-term Care Treatments

esnetwork.ca Last Updated: February 11, 2021

Bamlanivimab Implementation Panel

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: January 14, 2021

Also available in Français

Bamlanivimab in the Treatment of Outpatients With COVID-19: A Critical Appraisal of an Interim Analysis of the BLAZE-1 Trial

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: January 12, 2021

Also available in Français